LifeSci Capital analyst Charles Zhu has maintained their bullish stance on CMPX stock, giving a Buy rating on October 27.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Charles Zhu has given his Buy rating due to a combination of factors that highlight Compass Therapeutics’ promising developments and financial stability. The company reported positive updates on its pipeline programs, particularly the narrowed guidance for the PFS/OS readout of the COMPANION-002 trial, which indicates a continued trend of decreased mortality. This trial involves tovecimig, a drug with FDA Fast Track Designation, which is expected to have significant implications in the treatment of biliary tract cancer.
Furthermore, Compass Therapeutics has demonstrated progress in its clinical trials, such as the new response in the CTX-8371 trial, which has shown a favorable response rate without dose-limiting toxicities. The company’s financial position is also strong, with $220 million in cash and equivalents, providing a runway into 2028. These factors collectively suggest a positive outlook for the company’s growth and potential, justifying the Buy rating.
Zhu covers the Healthcare sector, focusing on stocks such as Kura Oncology, Zymeworks, and IDEAYA Biosciences. According to TipRanks, Zhu has an average return of 15.9% and a 61.70% success rate on recommended stocks.
In another report released on October 27, Piper Sandler also maintained a Buy rating on the stock with a $12.00 price target.